ConductScience.org, home

Paper39640222

Mechanisms and implications of recompensation in cirrhosis.

Piano S and 2 others. JHEP Rep, 2024. Cited by 32 papers, by iCite.

Cite this record

ConductScience Library. Mechanisms and implications of recompensation in cirrhosis. Papers, record 39640222. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39640222

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Mechanisms and implications of recompensation in cirrhosis.
PubMed
Journal
JHEP Rep
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
32
iCite
Relative citation ratio, by iCite
4.37, provisional
iCite
Revised in PubMed
2024-12-07
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Piano SSalvatore
2Reiberger TThomas
3Bosch JJaime

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References119

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138218352Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.J Hepatol2024https://conductscience.org/library/papers/38218352PubMed
216603731Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state.Am J Physiol Gastrointest Liver Physiol2006https://conductscience.org/library/papers/16603731PubMed
310744587Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy.Ann Intern Med2000https://conductscience.org/library/papers/10744587PubMed
429750389Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting.Liver Int2018https://conductscience.org/library/papers/29750389PubMed
537035457Dysregulated biomarkers of innate and adaptive immunity predict infections and disease progression in cirrhosis.JHEP Rep2023https://conductscience.org/library/papers/37035457PubMed
631607677Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Gastroenterol Hepatol2020https://conductscience.org/library/papers/31607677PubMed
735120736Baveno VII - Renewing consensus in portal hypertension.J Hepatol2022https://conductscience.org/library/papers/35120736PubMed
838478755Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case series.Hepatology2024https://conductscience.org/library/papers/38478755PubMed
937151732Increased sinusoidal pressure impairs liver endothelial mechanosensing, uncovering novel biomarkers of portal hypertension.JHEP Rep2023https://conductscience.org/library/papers/37151732PubMed
1033544313Regression of portal hypertension: underlying mechanisms and therapeutic strategies.Hepatol Int2021https://conductscience.org/library/papers/33544313PubMed
1125500203KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins.Gut2015https://conductscience.org/library/papers/25500203PubMed
1233746085A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement.J Hepatol2021https://conductscience.org/library/papers/33746085PubMed
1332535060Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.J Hepatol2020https://conductscience.org/library/papers/32535060PubMed
1436481475Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis.Clin Gastroenterol Hepatol2023https://conductscience.org/library/papers/36481475PubMed
1533930587Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: A long-term single-center experience.Clin Res Hepatol Gastroenterol2021https://conductscience.org/library/papers/33930587PubMed
168444409Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis.Hepatology1993https://conductscience.org/library/papers/8444409PubMed
1717335931Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats.J Hepatol2007https://conductscience.org/library/papers/17335931PubMed
1831426090Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population.Ann Intern Med2019https://conductscience.org/library/papers/31426090PubMed
1929861076Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.Lancet2018https://conductscience.org/library/papers/29861076PubMed
2011079009Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis.Arch Pathol Lab Med2000https://conductscience.org/library/papers/11079009PubMed

See all 119 referencesDownload CSV of references

Cited by20

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.

PMIDTitleJournalYearIn PapersSource
42706038[Characteristics and predictive factors of recompensation in patients with hepatitis B-related decompensated cirrhosis: a retrospective cohort study].Zhonghua Gan Zang Bing Za Zhi2026https://conductscience.org/library/papers/42706038PubMed
42694603From fibrosis regression to recompensation: bibliometric and clinical evidence mapping of disease modification in cirrhosis.Front Med (Lausanne)2026https://conductscience.org/library/papers/42694603PubMed
42564337Empagliflozin versus dapagliflozin in patients with liver cirrhosis: A comparative real-world study on hepatic decompensation.Hepatol Forum2026https://conductscience.org/library/papers/42564337PubMed
42544833Review article: Immunosuppression in Decompensated Autoimmune Hepatitis Cirrhosis - To Suppress or Not to Suppress?Aliment Pharmacol Ther2026https://conductscience.org/library/papers/42544833PubMed
42455326Periportal hyperintensity sign on Gd-BOPTA-enhanced hepatobiliary phase MRI identifies patients less likely to achieve recompensation in decompensated cirrhosis.Abdom Radiol (NY)2026https://conductscience.org/library/papers/42455326PubMed
42355650CT-Quantified Sarcopenic Visceral Obesity Is Negatively Associated with Recompensation in Patients with Decompensated Cirrhosis: A Retrospective Single-Center Study.J Clin Med2026https://conductscience.org/library/papers/42355650PubMed
42171974Immune-checkpoint inhibitors for advanced hepatocellular carcinoma in Child-Turcotte-Pugh-B cirrhosis: a liver-centric approach to outcomes beyond tumor progression.Hepatol Int2026https://conductscience.org/library/papers/42171974PubMed
42151601Comment on "Validation of Baveno VII criteria for recompensation in patients with decompensated cirrhosis treated by laparoscopic splenectomy and azygoportal disconnection".J Gastroenterol2026https://conductscience.org/library/papers/42151601PubMed
41811796Recompensation of Liver Cirrhosis: Definition, Mechanism, Etiological Differences, Prognosis, and Challenges.Can J Gastroenterol Hepatol2026https://conductscience.org/library/papers/41811796PubMed
41635624Reply to: "Predicting the need for early TIPS in patients with cirrhosis and ascites: More art than science".JHEP Rep2025https://conductscience.org/library/papers/41635624PubMed
41622173Recompensation following first decompensation in patients with alcohol-related cirrhosis.BMC Gastroenterol2026https://conductscience.org/library/papers/41622173PubMed
41589688Long-Term Outcomes After Endoscopic Sequential Therapy in Patients With Gastroesophageal Variceal Bleeding as the First Decompensated Event.Clin Transl Gastroenterol2026https://conductscience.org/library/papers/41589688PubMed
41528438Factors associated with recompensation and criteria for etiological suppression in patients with primary biliary cholangitis.J Gastroenterol2026https://conductscience.org/library/papers/41528438PubMed
41236657Ablation for hepatocellular carcinoma in hepatitis B-related recompensated vs. compensated cirrhosis.Eur Radiol2026https://conductscience.org/library/papers/41236657PubMed
41226066Diagnosis of Portal Hypertension.Diagnostics (Basel)2025https://conductscience.org/library/papers/41226066PubMed
41204950Validation of Baveno VII criteria for recompensation in patients with decompensated cirrhosis treated by laparoscopic splenectomy and azygoportal disconnection.J Gastroenterol2026https://conductscience.org/library/papers/41204950PubMed
41147778Unstable Recompensation: An Intermediate Subtype in Patients With HBV-Related Decompensated Cirrhosis.Aliment Pharmacol Ther2026https://conductscience.org/library/papers/41147778PubMed
40873069[Clinical research progress in different stages of recompensated cirrhosis].Zhonghua Gan Zang Bing Za Zhi2025https://conductscience.org/library/papers/40873069PubMed
40556980Therapeutic Potential of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Liver Disease: Focus on Cirrhosis.Cureus2025https://conductscience.org/library/papers/40556980PubMed
39870944Preventing the progression of cirrhosis to decompensation and death.Nat Rev Gastroenterol Hepatol2025https://conductscience.org/library/papers/39870944PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39640222

GET https://conductscience.org/api/papers/v1/39640222/references?page=2